Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 6:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 205 matching trials from the live ClinicalTrials.gov search.
Conditions
Dry Eye
Interventions
doxycycline, placebo
Drug
Lead sponsor
Alacrity Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Timeline
2007
U.S. locations
1
States / cities
Andover, Massachusetts
Conditions
Dry Eye, Dry Eye Disease (DED), Dry Eye Disease With Severe Keratitis
Interventions
TTAX03, Saline (NaCl 0,9 %) (placebo)
Biological
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Berkeley, California • Deerfield Beach, Florida • Chaska, Minnesota + 6 more
Conditions
Dry Eye Disease
Interventions
Intense pulsed light with C.STIM device
Device
Lead sponsor
Quantel Medical
Industry
Eligibility
22 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Lexington, Kentucky • Raleigh, North Carolina • Nashville, Tennessee + 1 more
Conditions
Dry Eye Syndromes
Interventions
Ecabet 2.83%, Ecabet 3.70%, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
3
States / cities
Lewiston, Maine • Andover, Massachusetts • Dover, New Hampshire
Suspended No phase listed Observational

Sjogren's Lung Study

NCT04843345
Conditions
Sjogren's Syndrome, Interstitial Lung Disease, Primary Pulmonary Lymphoma (Disorder), Chronic Bronchiolitis, Bronchiectasis, Lung Diseases, Cystic Lung Disease, Lymphocytic Interst. Pneumonitis
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Stanford, California
Conditions
Dry Eye
Interventions
NOVA22007 ''Cyclosporine'', vehicle/placebo
Drug
Lead sponsor
Santen SAS
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lewiston, Maine
Conditions
Dry Eye Disease (DED)
Interventions
NOV03, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Glendale, California + 25 more
Conditions
Dry Eye
Interventions
DE-101 ophthalmic suspension, DE-101 ophthalmic suspension vehicle
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
10
States / cities
Inglewood, California • Torrance, California • Bloomfield, Connecticut + 7 more
Conditions
Dry Eye
Interventions
Omega 3 fatty acid, Placebos
Drug
Lead sponsor
OmegaD LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Newport Beach, California • Westminster, California • Largo, Florida + 11 more
Conditions
Dry Eye Syndrome
Interventions
RGN-259, Placebo
Drug
Lead sponsor
ReGenTree, LLC
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Andover, Massachusetts
Conditions
Dry Age-Related Macular Degeneration, Geographic Atrophy
Interventions
iPSC-derived RPE/PLGA transplantation
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 95 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Conditions
Age-Related Macular Degeneration, Macular Degeneration, Age-Related, Dry Macular Degeneration, Geographic Atrophy
Interventions
Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
12
States / cities
Davis, California • Palo Alto, California • Sacramento, California + 7 more
Conditions
Meibomian Gland Dysfunction, Dry Eye
Interventions
Systane iLux thermal pulsation treatment
Procedure
Lead sponsor
Periman Eye Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Completed Phase 3 Interventional Results available

Study of SkQ1 as Treatment for Dry-eye Syndrome

NCT03764735
Conditions
Dry Eye Syndrome
Interventions
Low Dose - SkQ1, High dose - SkQ1, SkQ1 (Vehicle)
Drug
Lead sponsor
Mitotech, SA
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • Newport Beach, California • Louisville, Kentucky + 4 more
Conditions
Improvement of Dry Eye Disease
Interventions
Forma Eye Applicator
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Aurora, Colorado • Portsmouth, New Hampshire • Austin, Texas
Conditions
Dry Eye Disease
Interventions
AR-15512 Ophthalmic Solution, AR-15512 Ophthalmic Solution Vehicle
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 12 more
Recruiting Phase 4 Interventional

Evaluation of Lacrifill

NCT07796178
Conditions
Dry Eye, Ocular Surface Disease, Cataract Surgery, Eyes Dry Feeling of
Interventions
Lacrifill, Saline
Drug
Lead sponsor
Eye Research Associates, LLC
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Pittsburg, Kansas • Kansas City, Missouri
Conditions
Dry Eye Disease
Interventions
iNexin™ (0.08% aCT1), iNexin™ (0.4% aCT1), iNexin™ (2.0% aCT1), Vehicle (eye drop formulation without aCT1)
Drug
Lead sponsor
Xequel Bio, Inc.
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Andover, Massachusetts
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution, AR-15512 vehicle ophthalmic solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
23
States / cities
Chico, California • Fullerton, California • Newport Beach, California + 20 more
Completed Phase 2 Interventional Results available

Eyelid Androgen Treatment in Dry Eye

NCT06154200
Conditions
Aqueous Tear Deficiency, Meibomian Gland Dysfunction of Bilateral Eyes (Disorder)
Interventions
Testosterone gel 4.5%, Vehicle gel
Drug
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Fullerton, California
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine, Refresh Plus
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Greensboro, North Carolina
Conditions
Dry Eye Syndrome
Interventions
EGP-437 with EyeGate® II System, Sodium citrate buffer solution with EyeGate® II System
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Andover, Massachusetts • North Andover, Massachusetts
Conditions
Glaucoma, Dry Eye Syndrome, Conjunctivitis
Interventions
Not listed
Lead sponsor
Robin, Alan L., M.D.
Individual
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Evaporative Dry Eye Disease, Meibomian Gland Dysfunction
Interventions
ELM
Device
Lead sponsor
Eyedetec Medical, Inc.
Industry
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Citrus Heights, California